Artelo Biosciences, Inc. ARTL · Stock Open Artelo Biosciences, Inc. in new tab
Artelo Biosciences, Inc. Analysis (ARTL)
Is Artelo Biosciences, Inc. a good investment? Artelo Biosciences, Inc. (ARTL) is currently trading at 3.83 USD.
Earnings Schedule: Artelo Biosciences, Inc. is expected to release its next earnings report on Nov. 17, 2026. The market consensus estimate for Forward EPS is -0.88.
Investor FAQ
Does Artelo Biosciences, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Artelo Biosciences, Inc.?
Artelo Biosciences, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 17, 2026. The company currently has a trailing EPS of -101.07.
Company Profile
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
| Split Date | Split Ratio to 1 |
|---|---|
| Aug. 10, 2022 | 1:15 |
| June 13, 2025 | 1:6 |
| March 10, 2026 | 1:3 |
| Aug. 31, 2026 | 1:9 |
Community Discussion